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Abstract
Background: Targeted alpha therapy has been postulated to have great potential for the treatment of small
clusters of tumour cells as well as small metastases. 213Bismuth, an α-emitter with a half-life of 46 min, has shown
to be effective in preclinical as well as in clinical applications. In this study, we evaluated whether 213Bi-[DOTA0,
Tyr3]-octreotate (213Bi-DOTATATE), a 213Bi-labelled somatostatin analogue with high affinity for somatostatin
receptor subtype 2 (SSTR2), is suitable for the treatment of larger neuroendocrine tumours overexpressing SSTR2
in comparison to its effectiveness for smaller tumours. We performed a preclinical targeted radionuclide therapy
study with 213Bi-DOTATATE in animals bearing tumours of different sizes (50 and 200 mm3) using two tumour
models: H69 (human small cell lung carcinoma) and CA20948 (rat pancreatic tumour).
Methods: Pharmacokinetics was determined for calculation of dosimetry in organs and tumours. H69- or
CA20948-xenografted mice with tumour volumes of approximately 120 mm3 were euthanized at 10, 30, 60 and
120 min post injection of a single dose of 213Bi-DOTATATE (1.5–4.8 MBq). To investigate the therapeutic efficacy
of 213Bi-DOTATATE, xenografted H69 and CA20948 tumour-bearing mice with tumour sizes of 50 and 200 mm3
were administered daily with a therapeutic dose of 213Bi-DOTATATE (0.3 nmol, 2–4 MBq) for three consecutive
days. The animals were followed for 90 days after treatment. At day 90, mice were injected with 25 MBq 99mTc-DMSA
and imaged by SPECT/CT to investigate possible renal dysfunction due to 213Bi-DOTATATE treatment.
Results: Higher tumour uptakes were found in CA20948 tumour-bearing animals compared to those in H69
tumour-bearing mice with the highest tumour uptake of 19.6 ± 6.6 %IA/g in CA20948 tumour-bearing animals,
while for H69 tumour-bearing mice, the highest tumour uptake was found to be 9.8 ± 2.4 %IA/g. Nevertheless, as
the anti-tumour effect was more pronounced in H69 tumour-bearing mice, the survival rate was higher.
Furthermore, in the small tumour groups, no regrowth of tumour was found in two H69 tumour-bearing mice
and in one of the CA20948 tumour-bearing mice. No renal dysfunction was observed in 213Bi-DOTATATE-treated
mice after the doses were applied.
Conclusions: 213Bi-DOTATATE demonstrated a great therapeutic effect in both small and larger tumour lesions.
Higher probability for stable disease was found in animals with small tumours. 213Bi-DOTATATE was effective in
different neuroendocrine (H69 and CA20948) tumour models with overexpression of SSTR2 in mice.
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Background
Peptide receptor radionuclide therapy (PRRT) is an ef-
fective treatment option for patients with an inoperable
neuroendocrine tumour (NET) or with metastatic dis-
ease [1, 2]. Approximately 80 % of patients with NET
show great anti-tumour response upon PRRT. The
most commonly used radiolabelled peptides for treat-
ment in NET are 177Lu-[DOTA0, Tyr3]- octreotate
(177Lu-DOTATATE) and 90Y-[DOTA0, Tyr3]- octreotide
(90Y-DOTATOC). 90Y and 177Lu are β-particles emit-
ting radionuclides, with a maximum tissue penetration
of 12 and 2 mm, respectively. For treatment of small
tumour clusters and metastases, β-emitters may lack ef-
ficacy due to the relatively large tissue penetration and
low linear energy transfer (LET). Targeted alpha therapy
(TAT) with α-emitters has been described to be more suit-
able for these purposes, since the path length in tissue of
α-particles is relatively short (in tissue 50–100 μm) com-
pared to that of β-particles. Moreover, α-particles have a
much higher LET (~100 keV/μm) and are therefore more
powerful than β-particles (0.2 keV/μm) for therapeutic ap-
plications [3]. Bismuth-213 (213Bi), an α-emitter with a T1/
2 of 45.6 min, has already been proven to be effective in
TAT [4–7]. Recently, a clinical trial showed a promising
anti-tumour effect in patients with progressive advanced
neuroendocrine liver metastasis refractory to 90Y-DOTA-
TOC or 177Lu-DOTATOC treatment after treatment with
213Bi-DOTATOC [8]. TAT with 213Bi-DOTATOC was
able to overcome the resistance against β radiation in pa-
tients with different neuroendocrine tumours, in metasta-
sis and in primary tumours, resulting in a high number of
long-lasting anti-tumour responses.
The objective of this study was to investigate the thera-
peutic efficacy of 213Bi-DOTATATE in tumours of differ-
ent sizes in mice (small vs large). Two different tumour
models with somatostatin receptor subtype 2 (SSTR2) ex-
pression were used: CA20948 (rat pancreatic tumour) and
H69 (human small cell lung carcinoma). Both tumours
have relatively high SSTR2 expression, and both have often
been applied as a model in preclinical studies of PRRT in
NET [9–11]. The radiation sensitivity of CA20948 for
low-LET radiation has been determined yielding α/β =
8.3 Gy [12]. The H69 cell line shows a higher radiation
sensitivity α/β = 2.3 Gy [13]. Radiation damage by the
high-LET α radiation from 213Bi is expected to follow a
linear (-exponential) curve which was comparable for both
cell lines.
For PRRT, the dose-limiting organs are bone marrow
and kidneys. 213Bi-DOTATATE shows accumulation in
the kidneys, resulting in high radiation doses to the kid-
neys; in this study, we therefore determined the safe
dose of radioactivity administered for TAT in this
mouse model. Renal function was evaluated after TAT
by SPECT/CT at different time points post treatment
using 99mTc-DMSA (dimercaptosuccinic acid), a renal
marker for tubular damage.
Methods
213Bi-eluate
A 213Bi/225Ac generator (222 MBq) was provided by the
Institute for Transuranium Elements (Karlsruhe,
Germany). Prior to elution, the generator was rinsed
using 0.01 M HCl (3 mL) and eluted using 0.1 M/0.1 M
HCl/NaI (0.6 mL). After elution, the generator was
rinsed with 0.01 M HCl and stored in 0.01 M HCl [4].
The activity of 213Bi was determined using a germanium
detector (MetorX, Genie 2000 software, Canberra) [14].
213Bi-DOTATATE labelling
Eluate containing 213Bi (0.1 M/0.1 M in HCl/NaI) was
added to a solution containing 7.0 nmol DOTATATE,
0.15 M TRIS buffer and 2.6 mM ascorbic acid in a total
reaction volume of 800 μL. The reaction mixture was in-
cubated for 5 min at 95 °C followed by 5 min at room
temperature. To chelate any unbound/free 213Bi, 50 nmol
DTPA (Sigma Aldrich, Zwijndrecht, The Netherlands)
was added (manuscript submitted). Analysis by instant
thin-layer chromatography (ITLC, Varian) and reverse-
phase high-performance liquid chromatography (HPLC,
2695 separation module, Alliance, Waters, Etten-Leur,
The Netherlands) of the labelled peptide was performed
to determine the incorporation yield (%) and radiochem-
ical purity (RCP) expressed as percentage of labelled
peptide of interest compared to other detectable com-
pounds [15]. The whole labelling procedure took on
average 20 min to produce a ready-to-inject vial.
99mTc-DMSA labelling
The 99mTc-DMSA kit was purchased from Mallinckrodt
(Petten, the Netherlands) and labelled according to the
indicated procedure.
Cell culture
The rat pancreatic tumour cell line CA20948 (derived
from a rat pancreas tumour at our institute) with high
SSTR2 expression was cultured in DMEM (Gibco, Life
Technologies) supplemented with 10 % heat-inactivated
fetal bovine serum. H69 tumour cells, human small cell
lung carcinoma cells with SSTR2 expression (American
Tissue Culture Collection, Wesel, Germany), were cul-
tured in RPMI 1640 (Gibco, Life Technologies) supple-
mented with 10 % heat-inactivated fetal bovine serum
and 50 IU/mL penicillin/streptomycin. All cells were
cultured at 37 °C in a 5 % CO2/humidified air
atmosphere.
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Animal models
All animal studies were in agreement with the Animal
Welfare Committee requirements of Erasmus MC and
conducted in accordance with accepted guidelines. Male
6–8-week-old BALB/c (nu/nu) nude mice were obtained
from Charles River (Kißlegg, Germany). Subcutaneous
tumours were established in mice by inoculation of ap-
proximately 5 × 106 cells (CA20948 or H69), suspended
in 200 μL sterile culture medium Hanks’ balanced salt
solution (HBSS) in the case of CA20948 cells. Three
days after inoculation of CA20948 cells, a tumour with a
tumour size ~50 mm3 (used for the “smaller” tumour-
size group) was reached, and 2 weeks after inoculation, a
tumour size ~200 mm3 (used for the “larger” tumour-
size group) was reached. For H69 cells, 200 μL, contain-
ing 1/3 Matrigel and 2/3 HBSS medium (Gibco, Life
Technologies), was used. The cells were injected sub-
cutaneously (s.c.) into the right flank of the mice. One
week after inoculation of tumour cells, tumours with a
volume of ~50 mm3 (used for the smaller tumour-size
group) could be detected, and after 3 weeks, tumour vol-
umes reached ~200 mm3 (used for the larger tumour-
size group). Tumour volumes were estimated using a
calliper.
Pharmacokinetics of 213Bi-DOTATATE as function of time
in different tumour models
When tumour volumes reached ~120 mm3, animals
were divided into five groups with seven animals in each
group for both H69 and CA20948 tumour-bearing ani-
mals. Four groups of mice received a single intravenous
(i.v.) injection of 213Bi-DOTATATE (200 μL) via the tail
vein, 3.8 ± 0.6 MBq/0.3 nmol/200 μL for H69 tumour-
bearing animals and 2.1 ± 0.2 MBq/0.3 nmol/200 μL for
CA20948 tumour-bearing animals. At 10, 30, 60 and
120 min post injection (p.i.), animals in the four groups
were euthanized and tissues and organs of interest (in-
cluding tumour, kidney, pancreas, spleen, liver, muscle,
blood, femur, femur marrow and adrenals) were col-
lected and counted using a gamma counter (Wallac
Wizard 3, PerkinElmer, USA). Control animals received
a single injection of 213Bi-DOTATATE plus an excess of
DOTATATE (10−6 M) i.v. via the tail vein (blocking
dose) to determine the non-receptor-specific binding of
213Bi-DOTATATE. The animals of the control group
were euthanized 60 min p.i.; tissues and organs of inter-
est were harvested and counted using a gamma counter.
Data was expressed in mean percentage of total injected
radioactivity per gram tissue (%IA/g) ± SD.
Targeted alpha therapy
Tumour cells were inoculated into the right flank of the
mice, and the tumours were allowed to grow until
tumour volumes of approximately 50 and 200 mm3 were
reached, respectively. On the day of treatment (T = 0 days),
the animals (H69-bearing animals: small tumour n = 10,
large tumour n = 7; CA20948-bearing animals: small
tumour n = 8, large tumour n = 5) were injected i.v. via the
tail vein with 213Bi-DOTATATE (2–4 MBq/0.3 nmol/
200 μL) for three consecutive days. The control group
(H69-bearing animals: small tumour n = 10, large tumour
n = 9; CA20948-bearing animals: small tumour n = 5, large
tumour n = 5) received i.v. via the tail vein three times
0.3 nmol/200 μL of unlabelled DOTATATE for three con-
secutive days.
All animals were followed for 90 days after treatment.
The behaviour and the health status of the animals were
observed daily, and the weight of the animals and the
tumour volumes were monitored twice a week.
Determination of renal function by 99mTc-DMSA imaging
Renal function imaging was performed by a four-headed
multi-pinhole SPECT/CT camera (Bioscan Inc., Wash-
ington D.C., USA). For 99mTc imaging, an energy peak at
140 keV was selected with an energy window width ±
10 %. A nine-pinhole aperture (diameter of each pinhole
1.4 mm) was used on each camera head. For the CT
topogram, an axial length of 27 mm was used to cover
the renal region. Animals were imaged under anaesthe-
sia by isoflurane and O2. The body temperature of the
animals was maintained using a heated bed. Renal im-
aging of H69 (control n = 4, 213Bi-DOTATATE treated n
= 8) and CA20948 tumour-bearing animals (control n = 2,
213Bi-DOTATATE treated n = 4) was performed 2 h after
i.p. administration of 99mTc-DMSA (25 MBq). 99mTc-
DMSA images were acquired for 12 min(20 projections,
60 s/projection) [16].
Absorbed dose in organs
The absorbed radiation dose (defined as the mean
absorbed dose in Gy) in organs and tumours was esti-
mated from the results obtained in the biodistribution
studies as described by Konijnenberg et al. [17] in a
spherical geometry using Monte Carlo code MCNP5
(version 1.4) for the electrons and γ-rays [18] and
MCNPX (version 2.5) [19] for the α-particles, all energy
emission spectra were taken from ICRP database [20],
and particle histories of 1 × 107 was used for simulation
to reduce the variation (<5 %) in the data. The mean
absorbed energies for the 10 MBq 213Bi-DOTATATE in-
jection were calculated for spheres of 1, 10, 100, 200,
300 and 500 mg containing tissue with a mass density of
1 g/mL to determine the spherical node S-values. A
homogeneous activity distribution over the sphere was
assumed. The absorbed dose Di was calculated for each
volume i according to the MIRD schema:
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Di ¼ Aie S i←ið Þ
with Ãi the time-integrated activity (TIA) in organ i and
S(i← i) the absorbed dose rate per unit activity (S-
value). Only the self-dose S-values were considered and
were obtained by interpolation between the sphere S-
values for the measured organs or tumour mass. For
small tumours, a minimum tumour mass of 50 mg was
used for the absorbed dose calculation. The Ãi in each
organ was determined for 213Bi and its daughters taking
the biodistribution into account according to the
methods shown in Additional file 1. The absorbed dose
to the kidneys was calculated both with the spherical S-
values and with the nephron model by Hobbs et al. [21].
Three hypothetical activity distributions were considered
for this heterogeneous model: (1) homogeneous in the
cortex, (2) proximal tubular cell uptake and (3) glomeru-
lar cell uptake.
Statistics
Statistical analysis was performed using t test and using
the nonparametric Mann-Whitney test. P values <0.05
were considered statistically significant. For statistical sig-
nificances in tumour growth patterns, one-way ANOVA
was used. Values are presented as the mean and the stand-
ard deviation (SD).
Results
An incorporation yield of ≥99 % and a RCP ≥ 85 % were
found for the radiopeptide, as determined by ITLC and
HPLC, respectively.
Pharmacokinetic studies
Biodistribution studies using 213Bi-DOTATATE in H69
tumour-bearing mice revealed relatively high tumour up-
take. The highest tumour uptake was reached at 30 min
p.i., 9.8 ± 2.4 %IA/g. Tumour uptake T1/2 was 7 ± 2 min,
and tumour clearance T1/2 was 2.3 ± 1.1 h. An even higher
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Fig. 1 a–f Selected pharmacokinetics of 213Bi-DOTATATE from Tables 1 and 2. 213Bi-DOTATATE pharmacokinetics in H69 tumour-bearing mice,
uptake in tumours (a) and kidney (b), and radioactivity in blood (c) are shown over time in H69 tumour-bearing animals. Same data are shown
for CA20948 tumour-bearing animals: uptake in tumours (d) and kidneys (e) and radioactivity in blood (f). Solid curves show the mean uptake
value expressed in %IA/g ± SD. The dotted curves indicate the 95 % confidence interval
Table 1 Pharmacokinetics of 213Bi-DOTATATE at 10, 30, 60 and
120 min post injection (p.i.) in H69 tumour-bearing animals,
expressed in mean %IA/g ± SD, n = 7
Uptake (%IA/g) 10 min p.i. 30 min p.i. 60 min p.i. 120 min p.i.
Tumour 7.5 ± 2.2 9.8 ± 2.4 9.8 ± 2.3 6.8 ± 3.2
Muscle 2.1 ± 0.8 1.1 ± 0.2 1.0 ± 1.4 0.5 ± 0.4
Kidney 44.0 ± 9.6 28.5 ± 3.7 26.2 ± 2.6 25.0 ± 3.8
Pancreas 3.2 ± 0.3 2.8 ± 0.3 1.8 ± 0.2 1.4 ± 0.2
Liver 2.1 ± 0.8 0.9 ± 0.09 0.4 ± 0.06 0.3 ± 0.05
Blood 8.1 ± 1.8 2.3 ± 1.1 0.6 ± 0.2 0.1 ± 0.06
Spleen 2.3 ± 0.6 1.0 ± 0.09 0.4 ± 0.07 0.2 ± 0.07
Adrenal 3.6 ± 1.2 2.0 ± 0.6 0.9 ± 0.4 0.7 ± 0.4
Femur 2.8 ± 0.4 1.5 ± 0.4 1.0 ± 0.5 0.4 ± 0.4
%IA/g =mean percentage of total injected radioactivity per gram tissue
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renal activity compared to tumour uptake was found at all
time points, the highest renal activity being found at
10 min p.i., 44 ± 10 %IA/g. At 120 min p.i., the renal activ-
ity still was 25 ± 3 %IA/g. Blood clearance in H69 tumour-
bearing animals was fast, and clearance T1/2 was 11 ±
2 min, see Fig. 1a–c. All other organs had relative low up-
take at 120 min p.i., < 2 %IA/g, see Table 1.
Tumour uptake of 213Bi-DOTATATE in CA20948
tumour-bearing mice was already highest at 10 min
p.i., 19.6 ± 6.6 %IA/g, and the tumour uptake T1/2 was
therefore unable to estimate. A clearance T1/2 of 2.2±
0.9 h was found for CA20948 tumours. Similar renal
activity was found in CA20948 tumour-bearing ani-
mals. Renal activity was highest at 10 min p.i., 52 ±
17 %IA/g. Renal clearance T1/2 was 10 ± 3 min,
whereas blood clearance T1/2 was 14 ± 1 min, see
Fig. 1d–f. At 120 min p.i., uptakes in other organs
remained low, < 2 %IA/g, see Table 2.
Table 2 Pharmacokinetics of 213Bi-DOTATATE at 10, 30, 60 and
120 min post injection (p.i.) in CA20948 tumour-bearing animals,
expressed in mean %IA/g ± SD, n = 7
Uptake (%IA/g) 10 min p.i. 30 min p.i. 60 min p.i. 120 min p.i.
Tumour 19.6 ± 6.6 15.1 ± 6.6 12.7 ± 1.6 11.2 ± 5.4
Muscle 3.1 ± 0.8 1.5 ± 0.8 1.4 ± 1.9 0.2 ± 0.2
Kidney 51.5 ± 16.6 26.0 ± 3.3 15.0 ± 1.5 18.0 ± 1.9
Pancreas 3.6 ± 0.2 3.1 ± 0.4 1.5 ± 0.3 1.2 ± 0.2
Liver 2.0 ± 0.2 1.0 ± 0.1 0.2 ± 0.04 0.2 ± 0.03
Blood 7.1 ± 1.0 2.6 ± 0.4 0.3 ± 0.2 0.07 ± 0.04
Spleen 2.0 ± 0.2 1.1 ± 0.4 0.2 ± 0.05 0.2 ± 0.04
Adrenal 3.4 ± 0.7 2.2 ± 0.8 0.6 ± 0.1 0.4 ± 0.1
Femur 2.4 ± 0.2 1.4 ± 0.2 0.6 ± 0.1 0.2 ± 0.04
%IA/g =mean percentage of total injected radioactivity per gram tissue
Fig. 2 Calculated absorbed radiation dose rates in the tumour and kidney after 10 MBq 213Bi-DOTATATE, based on the data obtained in the
biodistribution study. Absorbed dose rate as function of time in H69 tumour-bearing animals; tumour (a) and kidney (b). Same data are shown
of the tumour (c) and kidney (d) for CA20948 tumour-bearing animals. Red lines indicate the absorbed dose rate contributed by all alpha
particles and blue lines by all beta particles. The dotted lines indicate the individual absorbed dose rate of 213Bi, 213 Po, 209Tl and 209 Pb
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Dosimetry
Dosimetry calculations in both tumour models were
based on the data obtained from the biodistribution
studies at 10, 30, 60 and 120 min p.i. In H69
tumour-bearing mice, a relatively high tumour-
absorbed radiation dose was estimated: 0.45 Gy/MBq
injected 213Bi-DOTATATE calculated for 100 mg
tumour. The renal-absorbed dose was four times as high
as the tumour-absorbed radiation dose: 2 Gy/MBq
injected 213Bi-DOTATATE. The absorbed radiation dose
of 213Bi-DOTATATE in the pancreas, spleen and liver was
low compared to those in the tumour and kidney, 0.15,
0.06 and 0.06 Gy/MBq, respectively. Similar results were
observed in CA20948 tumour-bearing animals. A lower
tumour-absorbed radiation dose was found than that in
the kidneys: 0.78 Gy/MBq in the tumour vs 1.6 Gy/MBq.
Absorbed radiation doses in the pancreas, spleen and
liver were 0.13, 0.05 and 0.06 Gy/MBq, respectively.
For both tumour-bearing animal models, an absorbed
dose of < 0.02 Gy/MBq was found in the bone marrow.
Tumour- and kidney-absorbed radiation doses in H69
or CA20948 tumour-bearing animals were mainly caused
by the α-particles emitted. The absorbed dose rate was
higher in CA20948 than in H69 tumours, and the kidney-
absorbed radiation dose was similar; see Fig. 2a–d. For an
instantaneous uptake in the H69 tumour, its absorbed
dose would rise by 12 % to 0.50 Gy/MBq, whereas the
absorbed dose to the CA20948 tumour is less dependent
on the uptake kinetics: the dose is lowered by 2 % to
0.77 Gy/MBq when the same uptake kinetics as for the
H69 tumour is assumed.
Targeted alpha therapy
Therapeutic anti-tumour effects were observed in all ani-
mals treated with 213Bi-DOTATATE, see Fig. 3. The
tumour volume doubling time was 16 ± 6 days for the
H69 and 10 ± 5 days for the CA20948 tumours, without
any difference between the growth rate of small tumours
and large tumours. The mean times to reach the end vol-
ume of 2000 mm3 of the control and treated animals of
both tumour models are indicated in Table 3. For small
tumours, tumour sizes < 50 mm3 could not be measured
accurately; therefore, 50 mm3 was used as the minimum
tumour sizes in our calculation and this was in three cases
of H69 tumour-bearing animals with a small tumour and
in all cases of CA20948 tumour-bearing animals with a
small tumour. Overall calculated cumulative tumour-
absorbed dose in small tumours was higher than large
tumours. In CA20948 tumours, the cumulative tumour-
absorbed dose was higher than in H69 tumours.
Shrinkage of tumours was observed in H69 tumour-
bearing animals with large tumours and a delay of tumour
growth around 70 days after 213Bi-DOTATATE (cumula-
tive injected activity of 9.4 ± 0.7 MBq) treatment. In
CA20948 tumour-bearing animals with large tumours, the
inhibition of tumour growth was initiated around 30 days
after therapy (cumulative injected activity 10.2 ± 0.4 MBq
213Bi-DOTATATE), leading to a tumour growth delay
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Fig. 3 Overview of mean tumour volumes ± standard deviation (SD) in mm3 per group after treatment of 213Bi-DOTATATE (2–4 MBq per injection) or
unlabelled DOTATATE (control) in H69 and CA20948 tumour-bearing mice for three consecutive days. V0 is the starting tumour volume. The dotted
curves show the extrapolated growth curves of the tumours assuming 100 % survival of animals
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time of 50 days. Similar results were found in CA20948
tumour-bearing animals with small tumours after therapy
(cumulative injected activity 7.7 ± 0.4 MBq); a delay in
tumour growth of around 30 days was observed, and in
one of the animals, no tumour regrowth was observed.
The delay time was estimated excluding the animals with
cure or stable disease. In H69 tumour-bearing animals
with small tumours, a delay of tumour growth was found
for around 30 days after therapy (cumulative injected
activity 7.4 ± 0.5 MBq), and in two animals, no tumour
regrowth was observed until the end of the study at day
90. Here, the two animals with cure/stable disease were
excluded from the estimated delay time.
Survival
All animals treated with 213Bi-DOTATATE showed a
higher survival rate than the control animals, see Fig. 4.
In the control, non-TAT H69 tumour-bearing animals, a
median survival of 34 days was found for animals bear-
ing large tumours and 81 days for animals bearing
small tumours. H69 tumour-bearing animals with
small tumours had a median survival of > 90 days after
213Bi-DOTATATE therapy (control vs treated, P value
= <0.0001). Similar results were obtained in H69
tumour-bearing animals with large tumours after TAT;
a median survival > 90 days was found (control vs
treated, P value = 0.0195). In the CA20948 tumour-
bearing animals without TAT, a median survival of
29 days was found for animals bearing large tumours,
whereas for animals bearing small tumours, this was
35 days. After 213Bi-DOTATATE, a median survival of
70 days was found in the large-tumour-animal group
(control vs treated, P value = not significant) and
> 90 days in the small-tumour-animal group (control
vs treated, P value = 0.005).
99mTc-DMSA uptake in the kidney
Renal function was investigated in H69 and CA20948
tumour-bearing animals at day 90 after 213Bi-DOTATATE
therapy or unlabelled DOTATATE treatment. Renal func-
tion was determined by renal uptake of 99mTc-DMSA
(25 MBq). No significant differences in 99mTc-DMSA up-
take in the kidneys were observed in 213Bi-DOTATATE-
treated mice and control animals for both tumour models.
In H69 tumour-bearing mice, a mean renal uptake of 2.6
± 0.8 MBq (mean concentration of 2.9 ± 0.6 kBq/mm3) in
the control group (n = 4) vs 2.1 ± 0.9 MBq (mean concen-
tration of 2.9 ± 0.8 kBq/mm3) in 213Bi-DOTATATE-
treated animals (n = 8) was found. Similar results were ob-
tained in CA20948 tumour-bearing animals: mean uptake
of 2.1 ± 0.2 MBq (mean concentration of 3.1 ± 0.4 kBq/
mm3) in 213Bi-DOTATATE-treated animals (n = 4) and
2.1 ± 0.3 MBq (mean concentration 3.2 ± 0.3 kBq/mm3) in
control (n = 2) were found. Figure 5a–e shows 99mTc-
DMSA uptake in kidneys of both tumour models.
Discussion
In this study, we compared the efficacy of 213Bi-DOTA-
TATE TAT in tumours of different sizes in two different
tumour models, both with expression of SSTR2.
213Bi-
Table 3 An overview of mean time (days = d) to reach a tumour volume of 2000 mm3 after 213Bi-DOTATATE therapy
H69 small H69 large CA20948 small CA20948 large
Control 73 ± 19 d 38 ± 11 d 43 ± 20 d 27 ± 14 d
Therapy 102 ± 19 d 110 ± 19 d 76 ± 15 d 77 ± 25 d
Tumour dose (Gy) 5 ± 1 Gy 2.0 ± 0.6 Gy 17 ± 1 Gy 10 ± 5 Gy
Growth delay (control vs therapy) 28 ± 9 d*** 73 ± 24 d* 33 ± 17 d NS 50 ± 13 d**
NS not significant
* = P value ≤0.05; ** = P value ≤0.01; *** = P value ≤0.001
The tumour dose (Gy) ± SD was estimated based on the tumour size at T = 0 of therapy and the injected activity (MBq). Growth delay (days) was the ΔT for
tumour to reach 2000 mm3 of therapy group vs control group
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DOTATATE showed a very good therapeutic effect in
both small and large tumours in the two different tumour
models. Tumour-absorbed doses (Gy) in CA20948
tumour-bearing animals were higher compared to those
in H69 tumour-bearing mice. Despite these findings,
213Bi-DOTATATE showed greater therapeutic effects in
H69 tumour-bearing animals than in CA20948 tumour-
bearing animals; a higher survival rate was observed in
H69 tumour-bearing animals at the end of the study.
However, no significant difference in tumour (re)growth
inhibition time between the two tumour models was
found, even though the absorbed dose in the tumour was
higher in CA20948 tumour-bearing animals. In vitro,
CA20948 cells appeared also more radioresistant than
H69 cells; at external beam irradiation with 2 Gy, a sur-
vival fraction of H69 was 37 % [13] and for CA20498,
52 % was found [12].
In this study, we observed a higher anti-tumour effect
in small tumours. In H69 tumour-bearing mice with
small tumours, two animals showed stable disease and
in eight animals, a partial response was found after treat-
ment. In the case of CA20948 tumour-bearing animals
with small tumours, one animal showed stable disease
till the end of the study and partial response was found
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in eight of the animals after 213Bi-DOTATATE therapy.
In H69 and CA20948 tumour-bearing animals with large
tumours, a partial response was found. A longer tumour
growth delay was found in animals with large tumours
of both tumour models compared to small tumours. The
time a tumour takes to reach 2000 mm3 in small tu-
mours is longer than in large tumours; therefore, Δ delay
time for tumour growth was used. Nevertheless, in ani-
mals showing regrowth, the small tumours were less re-
sponsive than the large tumours in both models.
The reason for partial remission can be explained as
the distribution of the radiation-absorbed dose depends
on the tumour size, the physical properties of the radio-
nuclide and its possible inhomogeneous intratumoural
distribution. In those cases where the tumour dimen-
sions are smaller than the range of the ionizing particles,
a large proportion of the absorbed energy can “escape”,
resulting in a suboptimal effect of 213Bi-DOTATATE
TAT [22]. In larger tumours, also pronounced thera-
peutic effects were observed after 213Bi-DOTATATE
therapies in both tumour models. However, no complete
remissions were observed in these animals. Besides
tumour perfusion [23] and inhomogeneous distribution
of SSTR2, tumour size [17, 22], vessel density, permeabil-
ity and tumour growth doubling time can play a critical
role for the success of PRRT; this is especially true for α-
emitters, where the penetration depth in tissue is rela-
tively short (50–100 μm). In large tumours, often hetero-
geneity of receptor distribution [24] is observed,
resulting in insufficient efficacy of the treatment and
leading to probability survival of tumour cells. Therefore
multiple fractions of therapy might improve the effect in
larger tumours [25], especially in the case of TAT.
For somatostatin receptor-targeted PRRT, nephrotox-
icity is often the dose-limiting factor, since reabsorption
of radiolabelled somatostatin analogues by cells in the
proximal tubule of the nephron occurs [26].
In this study, the calculated renal-absorbed dose using
our simplified model was compared to the model de-
scribed by Hobbs et al. [21]. We assumed all renal up-
takes to be localized in the proximal tubular cells and
took the glomerular cells as target. The absorbed dose in
the glomeruli was 57 % lower than for the mean
absorbed kidney dose. On the other hand, the dose to
the glomeruli is almost a factor 20 higher when all activ-
ity was concentrated in the glomerular cells. The homo-
geneous mean absorbed dose we calculated with the
sphere model was 24 % higher than when calculated
with the cortex model from Hobbs et al. [21].
99mTc-DSMA can provide information on renal func-
tion after renal tubular damage and has been used as
renal marker in PRRT [27]. In this study, we did not find
any changes in renal function in animals after TAT
(highest cumulative activity used was 11.5 MBq 213Bi-
DOTATATE). Kidney histology was performed in
CA20948-bearing animals (data not shown), and no sig-
nificant differences were observed in control vs treated
animals. However, 213Bi-DOTATATE is known to accu-
mulate in the kidney, leading to a high renal-absorbed
dose. In patients, the maximum tolerated dose in kidney
is postulated to be 23–28 Gy [28–30]. Kidney protec-
tants during TAT are therefore advised [9, 31, 32], espe-
cially when higher treatment activities are used. In
another study, we found a maximum tolerated activity of
21.2 ± 1.7 MBq in the presence of i.p. L-lysine as kidney
protectant prior to the 213Bi-DOTATATE treatment; in
the absence of L-lysine, the maximum tolerated activity
was <13.1 ± 1.2 MBq (manuscript in preparation).
Even though we have not been able to achieve complete
remission of all tumours, this study demonstrated that
TAT can be effective for the treatment of both large and
small tumours. These findings are in line with those of
Kratochwil et al. [8] who demonstrated the effectiveness
of TAT in eight patients refractory to PRRT with 177Lu
and 90Y. We therefore believe that TAT is most promising
for the treatment of NET. In combination with PRRT
using 90Y and 177Lu peptides [33, 34], even greater thera-
peutic efficacy might be achieved, especially for in the
treatment of patients with larger NET.
Conclusions
TAT with 213Bi-DOTATATE shows very good therapeutic
efficacy for the treatment of both large and small tumours
in these mouse models. In small tumours, 213Bi-DOTA-
TATE demonstrated greater anti-tumour effect by its
higher probability for inducing stable disease. Furthermore,
TAT using 213Bi-DOTATATE demonstrated to be safe in
our experimental setting, with kidneys as dose-limiting or-
gans. 213Bi-DOTATATE therefore held great promise for
targeted therapy for neuroendocrine tumours that express
SSTR2.
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